Huntington's disease is an autosomal dominant neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. It is caused by CAG repeat expansion in the HTT gene and typically manifests in mid-adulthood. Disease progression leads to severe disability over time.
The FDA said uniQure’s Phase I/II data for Huntington’s disease gene therapy AMT-130 are not adequate for a marketing application. The agency recommended a new randomised, double-blind, sham surgery-controlled study.
UniQure shares fell sharply after FDA comments appeared to raise concerns about the invasive delivery method for Huntington's disease therapy AMT-130. The company had planned a 2026 BLA filing after Phase I/II data showed a 75% slowing of disease progression at 36 months.
A phase 3 clinical trial has launched for pridopidine as a potential ALS treatment, while AI research identified 18 FDA-approved drugs that may extend survival. Separate studies found a promising three-drug combination for sporadic ALS using new cell models.
Huntington's disease provides neuroscience with a uniquely clear genetic model for studying brain disorders, featuring a single identifiable mutation and predictable disease progression. The condition serves as a testing ground for cutting-edge therapies and raises fundamental questions about brain regeneration. Its scientific clarity combined with a united patient and research community makes it an invaluable resource for advancing neurological understanding.
Sarepta Therapeutics received FDA feedback supporting supplemental applications for AMONDYS 45 and VYONDYS 53, while New Zealand approved a Phase 1 trial for Huntington's Disease candidate SRP-1005. The company faces significant share price declines despite these developments, with analysts showing wide disagreement on valuation targets ranging from $5 to $80.
uniQure disclosed the FDA will not accept Phase I/II data alone for AMT-130 approval, causing shares to drop 49%. The company held regulatory meetings and reported $622.5 million in cash while investors face an April 13 class action deadline.
The FDA has denied or discouraged at least eight drug applications in the past year, including treatments for rare diseases, raising concerns about regulatory consistency and the future of experimental therapies.
The FDA informed uniQure that Phase 1/2 study data for AMT-130 in Huntington's disease is insufficient to support a biologics license application, recommending a prospective, randomized, double-blind, sham surgery-controlled study instead.
uniQure reports Q4 2025 results as investors await clarity on AMT-130 Huntington's disease gene therapy following FDA's November indication that Phase I/II data unlikely to support biologics license application.
uniQure received FDA feedback stating current AMT-130 data unlikely to support accelerated approval for Huntington's disease, while securities fraud lawsuits challenge prior disclosures. Fresh Fabry disease trial data showed elevated enzyme activity but prompted a dosing pause for safety review.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07601516 |
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China |
COMPLETED | PHASE4 |
| NCT07536061 |
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease |
NOT_YET_RECRUITING | PHASE1 |
| NCT07246941 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease |
RECRUITING | PHASE1 |
| NCT06634628 |
iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009 |
RECRUITING | EARLY_PHASE1 |
| NCT06585449 |
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease |
RECRUITING | PHASE1 |
| NCT05655520 |
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease |
TERMINATED | PHASE3 |
| NCT05107128 |
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) |
COMPLETED | PHASE2 |
| NCT04120493 |
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03664804 |
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease |
COMPLETED | PHASE1 |
| NCT03628235 |
HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States |
COMPLETED |
